

Subt. For, PTO-1449				Docket Number ALT-006US1 (1009/007)		Application Number 09/779,439	
INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Antoine Noujaim			
				Filing Date February 8, 2002		Group Art Unit 2152	
Sheet	1	OF	1				

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

Foreign Patent Documents							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)		
	A1	Schultz, Birgit C. et al., <i>Cancer Immunol.</i> , "Anti-idiotypic therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1)", 46:201-212 , 1998.
	A2	Madiyalakan, R. et al., <i>HYBRIDOMA</i> , "Antiidiotype Induction Therapy: Evidence for the Induction of Immune Response Through the Idiotypic Network in Patients With Ovarian Cancer After Administration of Anti-CA125 Murine Monoclonal Antibody B43.13", 14:199-203 , 1995.
	A3	Reinhartz, S. et al., <i>HYBRIDOMA</i> , "Evaluation of Immunological Responses in Patients with Ovarian Cancer Treated with the Anti-idiotypic Vaccine ACA125 by Determination of Intracellular Cytokines—A Preliminary Report", 18:41-45 , 1999.
	A4	Schlebusch, Harald, et al., <i>HYBRIDOMA</i> , "A Monoclonal Antiidiotypic Antibody ACA 125 Mimicking the Tumor-Associated Antigen CA 125 for Immunotherapy of Ovarian Cancer", 14:167-174 , 1995.
	A5	Kohler, S. et al., <i>Gynakologische Tumoren</i> , "Ammuntherapie des Ovarial-karzinoms mit dem monoklonalen anti-idiotypischen Antikörper ACA 125-Ergebnisse der Phase-ib-Studie", 58:180-186 , 1998.
	A6	Leveugle, B. et al., <i>XP-002194280 (#2424)</i> , "PSA-directed Immunotherapy of Prostate Cancer".
	A7	Wagner, Uwe A. et al., <i>Biotechnology Therapeutics</i> , "Immunotherapy of Advanced Ovarian Carcinomas by Activation of the idiotypic Network", 3:81-89 , 1992.
	A8	
	A9	
	B1	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	